Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC

Other illness

• Another malignancy other than PDAC.
• Current or history of brain metastasis.

Other

• Patient with known genetic status for whom other treatments are available e.g. BRCA, MSI-H.

• Adult patient (18 years or older) with newly diagnosed metastatic PDAC or locally advance PDAC disease.
• HLA genotyping confirmed with a high-resolution method.
• Confirmed KRAS G12V or KRAS G12D mutation in tumour using biopsy sample.
• Fertile male and female patients must use a highly effective contraceptive method before, during, and for at least 6 months after the last mutKRAS TCR infusion. Acceptable contraception for women includes implants, injectables, combined oral contraceptives, intrauterine devices (IUDs), sexual abstinence, or a partner who has been vasectomized for at least 6 months. Acceptable contraception for male includes having had a vasectomy for at least 6 months, sexual abstinence, to condoms plus spermicide. Fertile female and male patients must adhere to any treatment-specific pregnancy prevention guidelines for cyclophosphamide (refer to SmPC).
• Confirmed clinical benefit to SoC treatments and absence of disease progression according to the PI judgement.
• Measurable disease by RECIST 1.1 criteria at the time of first treatment. Baseline imaging (for example, diagnostic CT of chest/abdomen/pelvis and imaging of the affected extremity or brain, as appropriate), or magnetic resonance imaging (MRI) must be obtained within 8 weeks of the first planned T cell infusion. CT can be substituted for MRI in patients unable to have CT contrast.